Cargando…

Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications

Coronavirus, a causative agent of the common cold to a much more complicated disease such as “severe acute respiratory syndrome (SARS-CoV-2), Middle East Respiratory Syndrome (MERS-CoV-2), and Coronavirus Disease 2019 (COVID-19)”, is a member of the coronaviridae family and contains a positive-sense...

Descripción completa

Detalles Bibliográficos
Autores principales: Prabhakar, Pranav Kumar, Khurana, Navneet, Vyas, Manish, Sharma, Vikas, Batiha, Gaber El-Saber, Kaur, Harpreet, Singh, Jashanpreet, Kumar, Deepak, Sharma, Neha, Kaushik, Ajeet, Kumar, Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960567/
https://www.ncbi.nlm.nih.gov/pubmed/36839773
http://dx.doi.org/10.3390/pharmaceutics15020451
_version_ 1784895543756980224
author Prabhakar, Pranav Kumar
Khurana, Navneet
Vyas, Manish
Sharma, Vikas
Batiha, Gaber El-Saber
Kaur, Harpreet
Singh, Jashanpreet
Kumar, Deepak
Sharma, Neha
Kaushik, Ajeet
Kumar, Raj
author_facet Prabhakar, Pranav Kumar
Khurana, Navneet
Vyas, Manish
Sharma, Vikas
Batiha, Gaber El-Saber
Kaur, Harpreet
Singh, Jashanpreet
Kumar, Deepak
Sharma, Neha
Kaushik, Ajeet
Kumar, Raj
author_sort Prabhakar, Pranav Kumar
collection PubMed
description Coronavirus, a causative agent of the common cold to a much more complicated disease such as “severe acute respiratory syndrome (SARS-CoV-2), Middle East Respiratory Syndrome (MERS-CoV-2), and Coronavirus Disease 2019 (COVID-19)”, is a member of the coronaviridae family and contains a positive-sense single-stranded RNA of 26–32 kilobase pairs. COVID-19 has shown very high mortality and morbidity and imparted a significantly impacted socioeconomic status. There are many variants of SARS-CoV-2 that have originated from the mutation of the genetic material of the original coronavirus. This has raised the demand for efficient treatment/therapy to manage newly emerged SARS-CoV-2 infections successfully. However, different types of vaccines have been developed and administered to patients but need more attention because COVID-19 is not under complete control. In this article, currently developed nanotechnology-based vaccines are explored, such as inactivated virus vaccines, mRNA-based vaccines, DNA-based vaccines, S-protein-based vaccines, virus-vectored vaccines, etc. One of the important aspects of vaccines is their administration inside the host body wherein nanotechnology can play a very crucial role. Currently, more than 26 nanotechnology-based COVID-19 vaccine candidates are in various phases of clinical trials. Nanotechnology is one of the growing fields in drug discovery and drug delivery that can also be used for the tackling of coronavirus. Nanotechnology can be used in various ways to design and develop tools and strategies for detection, diagnosis, and therapeutic and vaccine development to protect against COVID-19. The design of instruments for speedy, precise, and sensitive diagnosis, the fabrication of potent sanitizers, the delivery of extracellular antigenic components or mRNA-based vaccines into human tissues, and the administration of antiretroviral medicines into the organism are nanotechnology-based strategies for COVID-19 management. Herein, we discuss the application of nanotechnology in COVID-19 vaccine development and the challenges and opportunities in this approach.
format Online
Article
Text
id pubmed-9960567
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99605672023-02-26 Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications Prabhakar, Pranav Kumar Khurana, Navneet Vyas, Manish Sharma, Vikas Batiha, Gaber El-Saber Kaur, Harpreet Singh, Jashanpreet Kumar, Deepak Sharma, Neha Kaushik, Ajeet Kumar, Raj Pharmaceutics Review Coronavirus, a causative agent of the common cold to a much more complicated disease such as “severe acute respiratory syndrome (SARS-CoV-2), Middle East Respiratory Syndrome (MERS-CoV-2), and Coronavirus Disease 2019 (COVID-19)”, is a member of the coronaviridae family and contains a positive-sense single-stranded RNA of 26–32 kilobase pairs. COVID-19 has shown very high mortality and morbidity and imparted a significantly impacted socioeconomic status. There are many variants of SARS-CoV-2 that have originated from the mutation of the genetic material of the original coronavirus. This has raised the demand for efficient treatment/therapy to manage newly emerged SARS-CoV-2 infections successfully. However, different types of vaccines have been developed and administered to patients but need more attention because COVID-19 is not under complete control. In this article, currently developed nanotechnology-based vaccines are explored, such as inactivated virus vaccines, mRNA-based vaccines, DNA-based vaccines, S-protein-based vaccines, virus-vectored vaccines, etc. One of the important aspects of vaccines is their administration inside the host body wherein nanotechnology can play a very crucial role. Currently, more than 26 nanotechnology-based COVID-19 vaccine candidates are in various phases of clinical trials. Nanotechnology is one of the growing fields in drug discovery and drug delivery that can also be used for the tackling of coronavirus. Nanotechnology can be used in various ways to design and develop tools and strategies for detection, diagnosis, and therapeutic and vaccine development to protect against COVID-19. The design of instruments for speedy, precise, and sensitive diagnosis, the fabrication of potent sanitizers, the delivery of extracellular antigenic components or mRNA-based vaccines into human tissues, and the administration of antiretroviral medicines into the organism are nanotechnology-based strategies for COVID-19 management. Herein, we discuss the application of nanotechnology in COVID-19 vaccine development and the challenges and opportunities in this approach. MDPI 2023-01-30 /pmc/articles/PMC9960567/ /pubmed/36839773 http://dx.doi.org/10.3390/pharmaceutics15020451 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Prabhakar, Pranav Kumar
Khurana, Navneet
Vyas, Manish
Sharma, Vikas
Batiha, Gaber El-Saber
Kaur, Harpreet
Singh, Jashanpreet
Kumar, Deepak
Sharma, Neha
Kaushik, Ajeet
Kumar, Raj
Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications
title Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications
title_full Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications
title_fullStr Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications
title_full_unstemmed Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications
title_short Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications
title_sort aspects of nanotechnology for covid-19 vaccine development and its delivery applications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960567/
https://www.ncbi.nlm.nih.gov/pubmed/36839773
http://dx.doi.org/10.3390/pharmaceutics15020451
work_keys_str_mv AT prabhakarpranavkumar aspectsofnanotechnologyforcovid19vaccinedevelopmentanditsdeliveryapplications
AT khurananavneet aspectsofnanotechnologyforcovid19vaccinedevelopmentanditsdeliveryapplications
AT vyasmanish aspectsofnanotechnologyforcovid19vaccinedevelopmentanditsdeliveryapplications
AT sharmavikas aspectsofnanotechnologyforcovid19vaccinedevelopmentanditsdeliveryapplications
AT batihagaberelsaber aspectsofnanotechnologyforcovid19vaccinedevelopmentanditsdeliveryapplications
AT kaurharpreet aspectsofnanotechnologyforcovid19vaccinedevelopmentanditsdeliveryapplications
AT singhjashanpreet aspectsofnanotechnologyforcovid19vaccinedevelopmentanditsdeliveryapplications
AT kumardeepak aspectsofnanotechnologyforcovid19vaccinedevelopmentanditsdeliveryapplications
AT sharmaneha aspectsofnanotechnologyforcovid19vaccinedevelopmentanditsdeliveryapplications
AT kaushikajeet aspectsofnanotechnologyforcovid19vaccinedevelopmentanditsdeliveryapplications
AT kumarraj aspectsofnanotechnologyforcovid19vaccinedevelopmentanditsdeliveryapplications